Recursion Pharmaceuticals (RXRX) Stock Forecast, Price Target & Predictions
RXRX Stock Forecast
Recursion Pharmaceuticals stock forecast is as follows: an average price target of $9.67 (represents a 45.63% upside from RXRX’s last price of $6.64) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.
RXRX Price Target
The average price target for Recursion Pharmaceuticals (RXRX) is $9.67 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $6.00. This represents a potential 45.63% upside from RXRX's last price of $6.64.
RXRX Analyst Ratings
According to 5 Wall Street analysts, Recursion Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for RXRX stock is 0 'Strong Buy' (0.00%), 1 'Buy' (20.00%), 4 'Hold' (80.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Recursion Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Gil Blum | Needham | $11.00 | $6.10 | 80.33% | 65.66% |
| Sep 03, 2024 | Scott Schoenhaus | KeyBanc | $12.00 | $6.07 | 97.69% | 80.72% |
| Sep 03, 2024 | Dennis Ding | Jefferies | $6.00 | $6.02 | -0.34% | -9.64% |
| Jun 26, 2024 | Scott Schoenhaus | KeyBanc | $16.00 | $8.76 | 82.65% | 140.96% |
The latest Recursion Pharmaceuticals stock forecast, released on Sep 04, 2024 by Gil Blum from Needham, set a price target of $11.00, which represents a 80.33% increase from the stock price at the time of the forecast ($6.10), and a 65.66% increase from RXRX last price ($6.64).
Recursion Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 4 |
| Avg Price Target | - | $9.67 | $11.25 |
| Last Closing Price | $6.64 | $6.64 | $6.64 |
| Upside/Downside | -100.00% | 45.63% | 69.43% |
In the current month, the average price target of Recursion Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Recursion Pharmaceuticals's last price of $6.64. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | Needham | Market Perform | Market Perform | Hold |
| Sep 04, 2024 | Needham | Buy | Buy | Hold |
| Sep 03, 2024 | KeyBanc | Overweight | Overweight | Hold |
| Sep 03, 2024 | Cowen & Co. | Hold | Hold | Hold |
| Sep 03, 2024 | Jefferies | Hold | Hold | Hold |
| Jun 26, 2024 | KeyBanc | Overweight | Overweight | Hold |
| May 10, 2024 | Needham | Buy | Buy | Hold |
| Apr 09, 2024 | Needham | Buy | Buy | Hold |
| Mar 04, 2024 | Needham | Buy | Buy | Hold |
| Jan 17, 2024 | Needham | Buy | Buy | Hold |
Recursion Pharmaceuticals's last stock rating was published by Needham on Sep 04, 2024. The company gave RXRX a "Market Perform" rating, the same as its previous rate.
Recursion Pharmaceuticals Financial Forecast
Recursion Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $10.89M | $10.10M | $11.02M | $12.13M | $13.68M | $13.05M | $7.65M | $5.30M | $2.50M | $2.53M | $2.55M | $2.56M |
| Avg Forecast | $30.00M | $35.00M | $5.00M | $5.00M | $20.83M | $11.87M | $12.10M | $12.72M | $13.40M | $12.62M | $11.96M | $11.10M | $19.90M | $11.24M | $11.87M | $12.81M | $23.80M | $6.84M | $5.33M | $83.95M | $6.03M | $2.67M | $2.73M | $2.67M |
| High Forecast | $30.00M | $35.00M | $5.00M | $5.00M | $20.83M | $11.87M | $12.10M | $12.72M | $13.40M | $16.22M | $11.96M | $11.10M | $31.04M | $11.24M | $11.87M | $12.81M | $23.80M | $6.84M | $5.33M | $83.95M | $6.03M | $2.67M | $2.73M | $2.67M |
| Low Forecast | $30.00M | $35.00M | $5.00M | $5.00M | $20.83M | $11.87M | $12.10M | $12.72M | $13.40M | $4.05M | $11.96M | $11.10M | $7.75M | $11.24M | $11.87M | $12.81M | $23.80M | $6.84M | $5.33M | $83.95M | $6.03M | $2.67M | $2.73M | $2.67M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.55% | 0.90% | 0.93% | 0.95% | 0.57% | 1.91% | 1.43% | 0.06% | 0.41% | 0.95% | 0.94% | 0.96% |
Recursion Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $11.10M, with a low forecast of $11.10M, and a high forecast of $11.10M. RXRX's average Quarter revenue forecast represents a 1.92% increase compared to the company's last Quarter revenue of $10.89M (Dec 23).
Recursion Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-98.93M | $-85.41M | $-81.72M | $-61.58M | $-60.98M | $-57.44M | $-62.76M | $-53.20M | $-62.70M | $-44.77M | $-38.57M | $-29.07M |
| Avg Forecast | $-30.00M | $-35.00M | $-5.00M | $-5.00M | $-20.83M | $-11.87M | $-12.10M | $-12.72M | $-13.40M | $-12.62M | $-11.96M | $-11.10M | $-19.90M | $-11.24M | $-11.87M | $-12.81M | $-23.80M | $-6.84M | $-5.33M | $-253.75M | $-6.03M | $-2.67M | $-25.15M | $-2.67M |
| High Forecast | $-30.00M | $-35.00M | $-5.00M | $-5.00M | $-20.83M | $-11.87M | $-12.10M | $-12.72M | $-13.40M | $-4.05M | $-11.96M | $-11.10M | $-7.75M | $-11.24M | $-11.87M | $-12.81M | $-23.80M | $-6.84M | $-5.33M | $-203.00M | $-6.03M | $-2.67M | $-20.12M | $-2.67M |
| Low Forecast | $-30.00M | $-35.00M | $-5.00M | $-5.00M | $-20.83M | $-11.87M | $-12.10M | $-12.72M | $-13.40M | $-16.22M | $-11.96M | $-11.10M | $-31.04M | $-11.24M | $-11.87M | $-12.81M | $-23.80M | $-6.84M | $-5.33M | $-304.51M | $-6.03M | $-2.67M | $-30.18M | $-2.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 4.97% | 7.60% | 6.89% | 4.81% | 2.56% | 8.39% | 11.77% | 0.21% | 10.39% | 16.74% | 1.53% | 10.87% |
undefined analysts predict RXRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Recursion Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Recursion Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-93.00M | $-93.02M | $-76.73M | $-60.79M | $-57.48M | $-58.32M | $-65.55M | $-55.98M | $-64.95M | $-48.45M | $-45.87M | $-30.95M |
| Avg Forecast | $-60.55M | $-55.71M | $-77.50M | $-79.92M | $-116.25M | $-122.71M | $-121.10M | $-121.10M | $-108.30M | $-80.61M | $-93.07M | $-102.53M | $-108.69M | $-93.34M | $-90.82M | $-84.42M | $-70.24M | $-91.73M | $-90.42M | $-267.02M | $-74.27M | $-67.81M | $-28.30M | $-57.32M |
| High Forecast | $-60.55M | $-55.71M | $-77.50M | $-79.92M | $-116.25M | $-122.71M | $-121.10M | $-121.10M | $-108.30M | $-73.28M | $-93.07M | $-102.53M | $-70.88M | $-93.34M | $-90.82M | $-84.42M | $-70.24M | $-91.73M | $-90.42M | $-213.62M | $-74.27M | $-67.81M | $-22.64M | $-57.32M |
| Low Forecast | $-60.55M | $-55.71M | $-77.50M | $-79.92M | $-116.25M | $-122.71M | $-121.10M | $-121.10M | $-108.30M | $-85.50M | $-93.07M | $-102.53M | $-139.40M | $-93.34M | $-90.82M | $-84.42M | $-70.24M | $-91.73M | $-90.42M | $-320.42M | $-74.27M | $-67.81M | $-33.97M | $-57.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.86% | 1.00% | 0.84% | 0.72% | 0.82% | 0.64% | 0.72% | 0.21% | 0.87% | 0.71% | 1.62% | 0.54% |
Recursion Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RXRX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Recursion Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $30.46M | $29.20M | $28.29M | $22.87M | $19.84M | $19.49M | $21.20M | $21.07M | $19.20M | $15.69M | $13.85M | $8.94M |
| Avg Forecast | $172.72M | $201.51M | $28.79M | $28.79M | $119.95M | $68.32M | $69.67M | $73.26M | $77.14M | $72.67M | $68.84M | $63.91M | $114.55M | $64.70M | $68.32M | $73.74M | $137.03M | $39.40M | $30.71M | $483.34M | $34.74M | $15.40M | $15.69M | $15.40M |
| High Forecast | $172.72M | $201.51M | $28.79M | $28.79M | $119.95M | $68.32M | $69.67M | $73.26M | $77.14M | $93.37M | $68.84M | $63.91M | $178.72M | $64.71M | $68.32M | $73.74M | $137.03M | $39.40M | $30.71M | $483.34M | $34.74M | $15.40M | $15.69M | $15.40M |
| Low Forecast | $172.72M | $201.51M | $28.79M | $28.79M | $119.95M | $68.32M | $69.67M | $73.26M | $77.14M | $23.34M | $68.84M | $63.91M | $44.63M | $64.70M | $68.32M | $73.74M | $137.03M | $39.40M | $30.71M | $483.34M | $34.74M | $15.40M | $15.69M | $15.40M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.27% | 0.45% | 0.41% | 0.31% | 0.14% | 0.49% | 0.69% | 0.04% | 0.55% | 1.02% | 0.88% | 0.58% |
Recursion Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $63.91M, based on 4 Wall Street analysts, with a range of $63.91M to $63.91M. The forecast indicates a 109.82% rise compared to RXRX last annual SG&A of $30.46M (Dec 23).
Recursion Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.40 | $-0.43 | $-0.38 | $-0.32 | $-0.31 | $-0.34 | $-0.38 | $-0.33 | $-0.38 | $-0.29 | $-0.33 | $-0.20 |
| Avg Forecast | $-0.25 | $-0.23 | $-0.32 | $-0.33 | $-0.48 | $-0.51 | $-0.50 | $-0.50 | $-0.45 | $-0.33 | $-0.38 | $-0.42 | $-0.45 | $-0.39 | $-0.37 | $-0.35 | $-0.29 | $-0.38 | $-0.37 | $0.10 | $-0.31 | $-0.28 | $-0.23 | $-0.24 |
| High Forecast | $-0.25 | $-0.23 | $-0.32 | $-0.33 | $-0.48 | $-0.51 | $-0.50 | $-0.50 | $-0.45 | $-0.30 | $-0.38 | $-0.42 | $-0.29 | $-0.39 | $-0.37 | $-0.35 | $-0.29 | $-0.38 | $-0.37 | $0.10 | $-0.31 | $-0.28 | $-0.23 | $-0.24 |
| Low Forecast | $-0.25 | $-0.23 | $-0.32 | $-0.33 | $-0.48 | $-0.51 | $-0.50 | $-0.50 | $-0.45 | $-0.35 | $-0.38 | $-0.42 | $-0.58 | $-0.39 | $-0.37 | $-0.35 | $-0.29 | $-0.38 | $-0.37 | $0.10 | $-0.31 | $-0.28 | $-0.23 | $-0.24 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.89% | 1.12% | 1.01% | 0.92% | 1.07% | 0.90% | 1.02% | -3.30% | 1.24% | 1.04% | 1.41% | 0.85% |
According to undefined Wall Street analysts, Recursion Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RXRX previous annual EPS of $NaN (undefined).
Recursion Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
| XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
| CNSP | CNS Pharmaceuticals | $0.11 | $0.50 | 354.55% | - |
| IMMX | Immix Biopharma | $1.58 | $7.00 | 343.04% | Buy |
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| RLAY | Relay Therapeutics | $5.85 | $19.40 | 231.62% | Buy |
| SANA | Sana Bio | $3.76 | $12.00 | 219.15% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.95 | $7.00 | 137.29% | Buy |
| AFMD | Affimed | $3.27 | $7.50 | 129.36% | Buy |
| ABSI | Absci | $4.00 | $6.00 | 50.00% | Buy |
| RXRX | Recursion Pharmaceuticals | $6.64 | $9.67 | 45.63% | Hold |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |
RXRX Forecast FAQ
Is Recursion Pharmaceuticals a good buy?
No, according to 5 Wall Street analysts, Recursion Pharmaceuticals (RXRX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 20.00% of RXRX's total ratings.
What is RXRX's price target?
Recursion Pharmaceuticals (RXRX) average price target is $9.67 with a range of $6 to $12, implying a 45.63% from its last price of $6.64. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Recursion Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for RXRX stock, the company can go up by 45.63% (from the last price of $6.64 to the average price target of $9.67), up by 80.72% based on the highest stock price target, and down by -9.64% based on the lowest stock price target.
Can Recursion Pharmaceuticals stock reach $10?
RXRX's highest twelve months analyst stock price target of $12 supports the claim that Recursion Pharmaceuticals can reach $10 in the near future.
What are Recursion Pharmaceuticals's analysts' financial forecasts?
Recursion Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $57.52M (high $57.52M, low $57.52M), average EBITDA is $-57.525M (high $-57.525M, low $-57.525M), average net income is $-481M (high $-481M, low $-481M), average SG&A $331.2M (high $331.2M, low $331.2M), and average EPS is $-1.987 (high $-1.987, low $-1.987). RXRX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $75M (high $75M, low $75M), average EBITDA is $-75M (high $-75M, low $-75M), average net income is $-274M (high $-274M, low $-274M), average SG&A $431.81M (high $431.81M, low $431.81M), and average EPS is $-1.13 (high $-1.13, low $-1.13).
Did the RXRX's actual financial results beat the analysts' financial forecasts?
Based on Recursion Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $44.58M, which missed the average analysts forecast of $55.81M by -20.13%. Apple's EBITDA was $-350M, beating the average prediction of $-55.807M by 527.26%. The company's net income was $-328M, missing the average estimation of $-377M by -13.04%. Apple's SG&A was $110.82M, missing the average forecast of $321.31M by -65.51%. Lastly, the company's EPS was $-1.58, beating the average prediction of $-1.558 by 1.43%. In terms of the last quarterly report (Dec 2023), Recursion Pharmaceuticals's revenue was $10.89M, missing the average analysts' forecast of $19.9M by -45.26%. The company's EBITDA was $-98.93M, beating the average prediction of $-19.895M by 397.26%. Recursion Pharmaceuticals's net income was $-92.996M, missing the average estimation of $-109M by -14.44%. The company's SG&A was $30.46M, missing the average forecast of $114.55M by -73.41%. Lastly, the company's EPS was $-0.4, missing the average prediction of $-0.449 by -10.86%